American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
August 14, 2024
Earnings Call Speaker Segments
Kirin Smith
executiveThanks, Dave, and I appreciate all of you being with us today. Following the close of trading today, we put out AMS' earnings press release for the second quarter of 2024. Should you require one, you'll find it on the company's site, www.ashs.com, listed among press releases beneath the Investors tab. Prior to handing things over to management, there are a few things I want to say regarding forward-looking statements. Be aware that any comments made during this call regarding the company's future expectations, plans and prospects are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. A variety of important factors, among them those covered in the company's SEC filings, could cause actual results to differ materially from what those forward-looking statements suggest; those filings include the quarterly report on Form 10-Q covering the 3-month period that ended March 31, 2024, the annual report on Form 10-K covering the year that ended December 31, 2023, and the definitive proxy statement for the Annual Meeting of Shareholders held on June 25, 2024. No obligation is assumed by the company to update any information in this conference call. Before handing the call to Ray, I want to remind everybody about our Q&A Policy: every participant gets time for one question and one follow-up. As always, we're glad to address further questions offline whenever you like. With that, I'll hand the call to Ray Stachowiak, Executive Chairman and CEO. Ray, please go ahead.
Ray Stachowiak
executiveThanks, Kirin. Hello, everyone, and good afternoon. We appreciate you being with us for the earnings conference call covering our second quarter of 2024. I'll start things off with a few comments, and after that I'll hand things over to Bob Hiatt, who serves as our Chief Financial Officer, so he can walk through the financial review of what we delivered in the second quarter. Once those prepared remarks are finished, we'll take your questions. So let's move to the results for the quarter. AMS turned in a strong second quarter, and all of us are extremely excited about what lies ahead in the coming year. We continue to show momentum in the marketplace and headway on several important fronts. This quarter brought a really encouraging initial upside from the Rhode Island deal we finalized back in May, producing a pretax benefit right away of $4.9 million; that figure reflects what the net assets we acquired were worth above and beyond what we paid for them. As I've noted on numerous occasions, we're lucky to sit on a strong balance sheet with plenty of capital on hand to put toward strategic efforts and business chances as they arise. The Rhode Island acquisition really shows what we can do: we put in about $3 million and came away with assets at fair market value totaling roughly $8 million. That was a smart use of our capital, no question. Our team keeps working to make the core business stronger, partnering with customers so they get more out of the equipment. Thanks to that approach, over the past 15 months we've signed 5 lease extensions with our 10 domestic Gamma Knife customers, and more are in the pipeline. We see these longer agreements as proof that our partnership model and financial flexibility work. Internationally, our retail results also keep building momentum. During Q2, procedure counts rose after we finished installing new equipment in Ecuador — a cutting-edge Gamma Knife Icon, which is the sole Gamma Knife used for non-invasive radiosurgery in that nation. Excellent second-quarter performance also came from our Gamma Knife in Peru, the only such device in the country. We shared news just last week that patients are now being treated at our Puebla, Mexico, center. The recently installed linear accelerator, or LINAC, there comes equipped with VMAT, IGRT, IMRT and radiosurgery functions, delivering the most sophisticated radiation therapy offered anywhere in our catchment area. Then, during the early part of July, we signed a joint venture agreement for a Gamma Knife facility in Guadalajara, Mexico, marking our fourth international center. Additionally, we keep putting money into three distinct business possibilities that we've talked about before. Late last year, we announced the first of these — a deal to buy a 60% majority stake along with three radiation therapy centers located in Rhode Island, and that transaction wrapped up this past May. In the U.S., these represent our very first retail centers, or direct patient services. Coming from our enlarged team and fresh pipeline, this new business is the first of its kind, and it plainly shows how ambitious we are as a company. As for the second possibility, it centers on the Certificate of Need, or CON for short, which we've been granted so we can build a radiation therapy facility in Bristol, Rhode Island. Then there's a third possibility: the CON we submitted an application for, concerning a proton beam radiation therapy center located in Rhode Island; between New York City and Boston, this proton beam radiation therapy center would stand as the sole such system. Following quarter one, we delivered yet another robust quarter, with total revenue reported at $7.1 million for the second quarter, marking a 27% rise year over year. Gross margin percentage landed at 35%, mirroring the shift in mix alongside powerful expansion within our retail segment. Furthermore, we generated more than $3.6 million, equating to $0.55 per share, during the quarter — a significant jump relative to the second quarter of the previous year. That amount includes an after-tax gain of about $3.7 million from the Rhode Island acquisition we made. For the second quarter of 2024, operating income broke even, helped by $361,000 in additional expenses related to completing that Rhode Island deal, but that compares with an operating loss of $325,000 in the second quarter of 2023, mostly because of lower impaired assets and removal costs. Our balance sheet remains strong; at the end of the second quarter we had over $14.5 million in cash, which is about $2.24 per share. Also, as of June 30, 2024, $3.95 million was still outstanding under our $7 million line of credit, and we paid that off early in the third quarter of 2024. Our approach remains disciplined when it comes to putting these resources to work, so that we can create additional revenue streams over the long term. As we look at the upcoming months, we expect to see more growth internationally, driven by expanded treatment capabilities in Ecuador, continued strong volume at our Peru center, and the opening of new centers in Guadalajara and Puebla, Mexico. With the Rhode Island acquisition recently closed, three new revenue streams have been added to our business, along with new business opportunities that are currently moving through a sales cycle that is long and complex. Having said that, I'll turn the call over to Bob for the financial review. Bob?
Bob Hiatt
executiveThanks, Ray, and hello everyone this afternoon. Revenue for the second quarter rose 27%, reaching $7.1 million, up from $5.7 million during the same quarter last year. As we mentioned earlier, we restructured our business segments so they better represent where our revenue comes from. Leasing revenue — what we now call the medical equipment leasing segment — came to $3.9 million in Q2 2024, versus $4.81 million a year earlier, which works out to a 19% decline. Our direct patient services, or retail segment, brought in $3.16 million for the quarter ending June 30, 2024, compared with 756,000 in the prior-year quarter — a 318% jump. That gain came from the Rhode Island acquisition plus higher volumes at our current retail sites. On top of that, upgrading the equipment in Ecuador boosted capacity and improved both patient experience and volume, while Peru's revenues grew thanks to promotion of the center across that country. In Florida, second quarter revenue for the proton therapy system reached $2.42 million, down 5%, mostly from ongoing cyclical shifts in volume. Proton therapy fractions totaled 1236 this quarter, versus 1370 in Q2 2023 — a 10% drop consistent with normal cyclical swings. Gamma Knife procedures revenue fell 9% to $2.74 million, hurt by lower revenues from two contracts that expired, though strong volume at our international sites nearly made up for it. For context, Gamma Knife procedures numbered 340 this quarter, against 309 a year earlier. Still, if you set aside those two expired customer contracts, Gamma Knife procedures climbed by 65, or 24%, in Q2 2024. Gross margin for Q2 2024 declined 2% to $2.47 million, versus 2.52 million in Q2 2023. As our retail segment expands with its lower gross margin percentages, overall margin percentages will come down going forward. Selling and administrative costs dropped 5% to 1.9 million in Q2 2024, compared with 2 million a year earlier. That reflected the expiration of the corporate office lease space, partly offset by sublease income tied to it. Interest expense came in at 385,000 for the 2024 period, against 277,000 in last year's comparable period. The rise stems from higher interest rates and more borrowings on the company's variable rate debt. Operating income for Q2 2024 was breakeven, reflecting $361,000 in extra costs tied to closing the Rhode Island acquisition and other new business opportunities. In last year's quarter, costs incurred chasing this deal totaled 250,000, and combined with higher selling expenses, that produced a second quarter loss of 325,000. The income tax benefit was $31,000 in Q2 2024, compared with a $35,000 income tax benefit in the same period a year ago. Taxes tied to the bargain purchase gain brought that gain down from 4.9 million to 3.7 million, and they have no effect on income tax expense. For the second quarter of 2024, net income attributable to American Shared Hospital Services came to $3.6 million, or $0.55 per diluted share, versus a net loss of $111,000, or $0.02 per diluted share, in the second quarter of 2023. That period-over-period improvement stemmed mainly from the bargain purchase gain. Fully diluted weighted average common shares outstanding stood at 6,583,000 and 6,336,000 for the second quarter of 2024 and 2023, respectively. Adjusted EBITDA, a non-GAAP financial measure, came in at $2 million for the second quarter of 2024, versus $1.9 million for the second quarter of 2023. During the 6 months ended June 30, 2024, revenue rose 17% to 12,272,000, compared with revenue of 10,493,000 in the first six months of 2023. Gamma Knife revenue fell 6% to 5,311,000 in the first half of 2024, versus 5,634,000 in the first half of 2023. Gamma Knife procedures totaled 613 in the first 6 months of 2024, up 2% from 602 Gamma Knife procedures in the comparable period of 2023, driven by a steady rise in international procedures. Proton therapy revenue grew 4% to 5,069,000 in the first half of 2024, versus 4,859,000 in the first half of 2023. Total proton therapy fractions reached 2,512 in the first 6 months of 2024, down 14% from 2,906 proton therapy fractions in the comparable period of 2023. Net income attributable to American Shared Hospital Services for the first 6 months of 2024 was $3.7 million, or $0.57 per diluted share, versus net income of $77,000, or $0.01 per diluted share, for the first 6 months of 2023. Adjusted EBITDA, a non-GAAP financial measure, was $3.8 million for the first 6 months of 2024, versus $3.8 million for the first 6 months of 2023. That slight decrease resulted mainly from higher fees connected to new business opportunities, including the company's acquisition in Rhode Island. As of June 30, 2024, cash, cash equivalents and restricted cash totaled $14.5 million, versus $13.8 million at December 31, 2023. Shareholders' equity, excluding non-controlling interest in subsidiaries, stood at $26.5 million, or $4.17 per outstanding share, at June 30, 2024, versus $22.6 million, or $3.59 per outstanding share, at December 31, 2023. That wraps up the formal portion of our presentation. Thank you for joining us today; we look forward to updating you on our progress in the quarters ahead. Dave, we'd now like to turn the call back to you and open it up for questions.
Marla Marin
analystJust one thing. I'd like to verify a few points. While you keep looking at ways to expand the direct side of things, you're also still chasing more chances on the leasing side. And on top of that, when you start upgrading the machinery at Sacred Heart, should we expect service disruptions at that location during 3Q and possibly 4Q too? Thanks.
Ray Stachowiak
executiveThanks for that, Marla. I appreciate it. Both of our segments have had our attention: the leasing segment, through which we lease out our equipment, and the retail segment, where we hold and run substantially majority control of our own centers delivering services straight to patients, plus our centers that bill either the patients or their insurance companies. Both areas are ones we're going after, yet I believe it's clear from the Rhode Island acquisition, the launch of our operation in Puebla, Mexico, and the signing of a new center in Guadalajara, Mexico that our emphasis and the business opportunities we're committing to lean more toward the retail segment; therefore, we view that retail segment quite favorably within our business model.
Marla Marin
analystThanks. And regarding any interruptions at the Sacred Heart location?
Ray Stachowiak
executiveI'm unable to speak about any specific facility.
Tony Kamin
analystHey, Ray. I just want to clarify something — the Rhode Island acquisition, I believe, wrapped up during the first or second week of May. That means the quarter you just reported didn't cover a full 3 months, right?
Ray Stachowiak
executiveThat's right.
Tony Kamin
analystAll right, that sounds excellent. Now, regarding whatever initial insights you might have so far — I realize it's quite soon — but with this kind of direct connection in place, is your team picking up anything useful? I'm also curious about how that ties into the planned proton beam facility in Rhode Island. You filed for the certificate. Has the schedule for that shifted at all since our previous call?
Ray Stachowiak
executiveAs far as when the CON application will move forward, we keep running into postponements when it comes to getting the hearing set for the CON, though it appears we're getting nearer to actually holding one. Honestly, we don't anticipate hearing anything discouraging coming out of that effort. On the learning side, we're continually gaining knowledge, yet our group already brings a lot of experience — me, Craig, and Greg Mercurio, our Senior Vice President of Radiation Oncology, who isn't joining us on this call, have probably accumulated 30 years or more apiece running and holding these kinds of facilities in various formats. No two scenarios are alike, so lessons will come. That means there's a learning curve we're working through. Still, we have a fantastic group of people whom I'd describe as extremely assured when it comes to running and holding these sites and turning them into successes. So here we are — this purchase came out of a bankruptcy proceeding, and that proceeding worked to our advantage. Often when you buy things, you assign value to the assets, and if those assets are worth under what you paid, you end up putting some goodwill on your books. This case is the reverse: we spent roughly $3 million, give or take. What we got were assets whose fair market value came to around $8 million — 4.9 million, whichever figure applies here, approximately — producing a gain from the deal, which is truly extraordinary. Beyond being able to account for that gain — 3.7 million after tax — we now hold three genuinely strong radiation therapy cancer centers across Rhode Island, and I believe you'll witness the upside of running and holding those over the quarters ahead.
Tony Kamin
analystAs someone who's held shares for a long time, it's genuinely thrilling to watch this much momentum and so many varied projects underway. I honestly can't remember a period quite like this one. So with that said, this is sort of my last question, though I do want to squeeze in one remark first. When it comes to the Rhode Island centers, are you ramping up marketing efforts or reworking the approach? Then for my actual final question: the news release includes a quote from Craig stating that we've kept seeing a substantial rise in the breadth of opportunities for consideration. Our sales pipeline remains extremely strong with additional projects. Could you offer any further detail on that? Thank you.
Ray Stachowiak
executiveWell, I'd say we keep our eyes and ears tuned in near the marketplace. Rhode Island was the outcome of that. I mean, this opportunity came to us because we kept our eyes and ears tuned in near the market on the ground — what's happening and what possibilities are out there; and we took a bit of a pause when Peter Gaccione, our CEO, passed away earlier this year, but we've bounced back. We've sort of reinforced our management team along with some of the duties and responsibilities, and we have a solid group of people chasing these opportunities. And it's likely a larger, stronger pipeline than we've ever had.
Ray Stachowiak
executiveAll right. Thanks, Dave, and thanks to each of you who took the time to be with us today; our future has us genuinely enthusiastic; in our view, AMS stands at a pivotal turning point, particularly in the wake of the Rhode Island deal we closed not long ago. We're eager to share news about the ongoing strides we're making. And, as ever, should anything come to mind before then, feel free to reach out to us straight away. We appreciate your lasting interest in American Shared Hospital Services.
Operator
operatorThat brings today's call to a close. We appreciate your participation in the presentation. You're welcome to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.